Anavex director Vander Velden receives 50,000 options

Q: What option did AVXL director Claus Vander Velden receive?

Claus Vander Velden received an option to buy 50,000 common shares on November 3, 2026. It has a $1.20 exercise price and expires November 2, 2036.

The option vests in three substantially equal annual installments beginning March 31, 2027, and has a $1.20 exercise price.

Available on EDGAR 11/06/2026 - 08:16 PM EST Accepted by SEC EDGAR 11/06/2026 - 08:16 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Anavex Life Sciences Corp. (AVXL) director Claus Vander Velden received a stock option for the right to buy 50,000 common shares on November 3, 2026. The option has a $1.20 exercise price and expires November 2, 2036. It vests in three substantially equal annual installments beginning March 31, 2027.

Insider Trade Summary

Grant/Award: 50,000 shares

Grant/Award 1 txn

Insider Velden Claus Vander

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) ^F1	50,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 50,000 options (Direct)

Holdings Before and After: Stock Option (Right to Buy), 0 to 50,000 options (Direct)

Footnotes (1)

F1. The option vests in three substantially equal annual installments beginning on March 31, 2027

Key Figures

Shares underlying option: 50,000 common shares Exercise price: $1.20 per share Vesting installments: 3 substantially equal annual installments +1 more

4 metrics

Shares underlying option 50,000 common shares Option granted November 3, 2026

Exercise price $1.20 per share Stock option

Vesting installments 3 substantially equal annual installments Beginning March 31, 2027

Option expiration November 2, 2036 Stock option

Key Terms

Stock Option (Right to Buy), exercise price, annual installments

3 terms

Stock Option (Right to Buy) financial

"the option for the right to buy 50,000 common shares"

exercise price financial

"the option's $1.20 exercise price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

annual installments financial

"the option vests in three substantially equal annual installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What option did AVXL director Claus Vander Velden receive?

Claus Vander Velden received an option to buy 50,000 common shares on November 3, 2026. It has a $1.20 exercise price and expires November 2, 2036.

When does Claus Vander Velden's AVXL option vest?

The option vests in three substantially equal annual installments beginning March 31, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Velden Claus Vander

(Last)

(First)

(Middle)

630 5TH AVENUE 20TH FLOOR

(Street)

NEW YORK

10111

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANAVEX LIFE SCIENCES CORP. [ AVXL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$1.2	11/03/2026		A		50,000		⁽¹⁾	11/02/2036	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. The option vests in three substantially equal annual installments beginning on March 31, 2027

	/s/Claus van der Velden	11/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR